ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer

• Published in: Science advances Vol. 9; no. 47; p. eadg2263
• Main Authors: Zhou, Yuzhen, Börcsök, Judit, Adib, Elio, Kamran, Sophia C, Neil, Alexander J, Stawiski, Konrad, Freeman, Dory, Stormoen, Dag Rune, Sztupinszki, Zsofia, Samant, Amruta, Nassar, Amin, Bekele, Raie T, Hanlon, Timothy, Valentine, Henkel, Epstein, Ilana, Sharma, Bijaya, Felt, Kristen, Abbosh, Philip, Wu, Chin-Lee, Efstathiou, Jason A, Miyamoto, David T, Anderson, William, Szallasi, Zoltan, Mouw, Kent W
• Format: Journal Article
• Language: English
• Published: United States 24.11.2023
• Subjects: Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Ataxia Telangiectasia; Ataxia Telangiectasia Mutated Proteins - genetics; Ataxia Telangiectasia Mutated Proteins - metabolism; DNA Damage; DNA Repair; Humans; Poly(ADP-ribose) Polymerases - genetics; Tumor Microenvironment; Urinary Bladder Neoplasms - genetics; Urinary Bladder Neoplasms - therapy

Ataxia-telangiectasia mutated (ATM) plays a central role in the cellular response to DNA damage and ATM alterations are common in several tumor types including bladder cancer. However, the specific impact of ATM alterations on therapy response in bladder cancer is uncertain. Here, we combine preclin...